Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-08-07
2007-08-07
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S314000, C514S326000, C514S341000, C514S367000, C544S238000, C546S167000, C546S211000, C546S275400, C548S375100
Reexamination Certificate
active
11477010
ABSTRACT:
The present invention provides pyrazole derived compounds of formula (I)useful for treating p38 kinase-associated conditions, where W, X, R1, R2, R3, R4, R5, R6and m are as defined herein. The invention further pertains to pharmaceutical compositions containing at least one compound according to the invention useful for treating p38 kinase-associated conditions, and methods of inhibiting the activity of p38 kinase in a mammal.
REFERENCES:
patent: 4200750 (1980-04-01), Warner, Jr. et al.
patent: 5712279 (1998-01-01), Biller et al.
patent: 5739135 (1998-04-01), Biller et al.
patent: 5760246 (1998-06-01), Biller et al.
patent: 6184231 (2001-02-01), Hewawasam et al.
patent: 6548529 (2003-04-01), Robl et al.
patent: 6706711 (2004-03-01), Hale
patent: 6706720 (2004-03-01), Atwal et al.
patent: 2002/0065270 (2002-05-01), Moriarty et al.
patent: 2002/0137747 (2002-09-01), Moriarty et al.
patent: 2003/0139435 (2003-07-01), Ahmed et al.
patent: 2004/0039033 (2004-02-01), Atwal et al.
patent: WO 02/062804 (2002-08-01), None
patent: WO02/096905 (2002-12-01), None
patent: WO 2003037274 (2003-05-01), None
Ahn, H.-S. et al., “Potent Tetracyclic Guanine Inhibitors of PDE1 and PDE5 Cyclic Guanosine Monophosphate Phosphodiesterases with Oral Antihypertensive Activity”, J. Med. Chem., vol. 40, No. 14, pp. 2196-2210 (1997).
Greene, T.W. et al., Protective Groups in Organic Synthesis, Third Editon, John Wiley & Sons, Inc., publ., pp. xi-xii (table of contents) (1999).
Henry, J.R. et al., “p38 mitogen-activated protein kinase as a target for drug discovery”, Drugs of the Future, vol. 24, No. 12, pp. 1345-1354 (1999).
Manning, G. et al., “The Protein Kinase Complement of the Human Genome”, Science, vol. 298, pp. 1912-1916, 1933-1934 (2002).
Moreland, L.W. et al., “Etanercept Therapy in Rheumatoid Arthritis: A Randomized, Controlled Trial”, Ann. Intern. Med., vol. 130, No. 6, pp. 478-486 (1999).
Raingeaud, J. et al., “MKK3- and MKK6-Regulated Gene Expression Is Mediated by the p3B Mitogen-Activated Protein Kinase Signal Transduction Pathway”, Molecular and Cellular Biology, vol. 16, No. 3, pp. 1247-1255 (1996).
Rankin, E.C.C. et al., “The Therapeutic Effects of an Engineered Human Anti-Tumour Necrosis Factor Alpha Antibody (CDP571) in Rheumatoid Arthritis”, British Journal of Rheumatology, vol. 34, No. 4, pp. 334-342 (1995).
Salituro, F.G. et al., “Inhibitors of p38 MAP Kinase: Therapeutic Intervention in Cytokine-Mediated Diseases”, Current Medicinal Chemistry, vol. 6, No. 9, pp. 807-823 (1999).
Klunge et al., “Radical Reactions of N-Heterocyclic Compounds, XV[1]”, Monatschefte fuer Chemie (1997), 128 (3) 261-270.
Das Jagabandhu
Dyckman Alaric J.
Leftheris Katerina
Liu Chunjian
Moquin Robert V.
Bristol--Myers Squibb Company
O'Brien Maureen P.
Saeed Kamal A.
LandOfFree
Pyrazole-amine compounds useful as kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrazole-amine compounds useful as kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrazole-amine compounds useful as kinase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3853451